Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

Fig. 5

Treg depletion synergizes with α-PD-1 but not α-TGFβ in tumor regression and long term survival. CCK168 tumors were treated as in Fig. 1b, except that 24 h prior to the first therapeutic drug dose, mice received intraperitoneal injection of an IgG control or α-CD25+ cell-depleting antibody. a) and b) Kaplan Meier survival plots for CCK168 tumor-bearing mice using using 2000 mm3 tumor size as cut off for survival. P < 0.05 = *, p < 0.01 = ** Gehan-Breslow-Wilcoxon test

Back to article page